What is HydroCision?
HydroCision, Inc. is a privately held medical device firm distinguished by its innovative FluidJet technology. This patented system enables precise soft tissue removal without generating heat, a critical advancement for various medical applications. The company's technology has found utility across wound care, urology, spine surgery, interventional pain management, and orthopedic sports medicine, positioning it as a key player in developing advanced surgical tools.
How much funding has HydroCision raised?
HydroCision has raised a total of $36.5M across 10 funding rounds:
Series F
$5.2M
Series G
$12.7M
Debt
$3M
Debt
$623K
Private Equity
$3M
Other Financing Round
$4M
Debt
$150K
Debt
$279K
Series F (2002): $5.2M, investors not publicly disclosed
Series G (2006): $12.7M, investors not publicly disclosed
Debt (2008): $3M, investors not publicly disclosed
Debt (2010): $623K, investors not publicly disclosed
Private Equity (2017): $3M led by Volcano Capital, LLC and BioVentures Investors, LLC
Other Financing Round (2017): $4M supported by Tradewind International
Debt (2020): $150K featuring PPP
Debt (2021): $279K backed by PPP
Key Investors in HydroCision
Volcano Capital, LLC
Volcano Capital, LLC is an evergreen fund focused exclusively on healthcare, providing capital and operational expertise to help entrepreneurs grow their businesses. They emphasize a collaborative approach and offer strategic guidance, legal, and financial support, along with access to a broad network of experienced operators and clinicians.
BioVentures Investors, LLC
BioVentures MedTech Funds is dedicated to investing in innovative companies developing advanced medical technologies to improve global healthcare outcomes. They focus on emerging and growth-stage MedTech companies, providing capital, guidance, and strategic advice to drive successful exits.
Oxford Bioscience Partners
Oxford Bioscience Partners is an international venture capital firm specializing in life science technology investments, with offices in Boston, Massachusetts and Seoul, Korea.
What's next for HydroCision?
The recent major strategic investment of $279K signals a pivotal phase for HydroCision, likely aimed at accelerating commercialization, expanding its patent estate, and penetrating new market segments within its established application fields. This infusion of capital, contributing to the company's overall $36.5M, suggests a strategic push towards scaling operations and solidifying its market presence. Future developments may include further technological refinements and broader adoption of its heat-free tissue removal solutions across the global healthcare landscape.
See full HydroCision company page
